Literature DB >> 18685353

Management of neuropathic pain.

Troels S Jensen1, Nanna Brix Finnerup.   

Abstract

PURPOSE OF REVIEW: Neuropathic pain is a chronic pain condition arising from injury or disease of the peripheral or central nervous system with a substantial impact on quality of life. This brief review focuses on the increasing evidence for effective treatments and discusses an evidence-based algorithm for treating neuropathic pain conditions. RECENT
FINDINGS: Randomized controlled trials have consistently shown efficacy of tricyclic antidepressants, gabapentin/pregabalin, opioids, tramadol, and serotonin and noradrenaline-reuptake inhibitors for the treatment of various neuropathic pain conditions, lidocaine patches for postherpetic neuralgia and cannabinoids for pain in multiple sclerosis. Carbamazepine or oxcarbazepine is the treatment of choice for trigeminal neuralgia. The efficacy of these drugs in other neuropathic pain conditions as well as the efficacy of lamotrigine and topical capsaicin is questionable, but they may be useful in a subgroup of patients.
SUMMARY: For each patient, considerations on the underlying pain mechanisms, immediate and potential long-term side effects, and price as well as comorbidities and concurrent medications will decide which drug should be the first choice, but until further progress is made towards a mechanism-based classification, treatment is likely to be a trial-and-error process where drug combinations may also be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18685353     DOI: 10.1097/SPC.0b013e3282eeb45f

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  8 in total

1.  Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.

Authors:  Tie-Jun Sten Shi; Su-Xing Leslie Liu; Henrik Hammarberg; Masahiko Watanabe; Zhi-Qing David Xu; Tomas Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

2.  Neuropathic pain referrals to a multidisciplinary pediatric cancer pain service.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Mark P Popenhagen; Linda L Oakes; Deqing Pei; Laura L Burgoyne
Journal:  Pain Manag Nurs       Date:  2012-08-25       Impact factor: 1.929

3.  Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey.

Authors:  Janet Weber; Marcus Schley; Matthias Casutt; Helmut Gerber; Guido Schuepfer; Roman Rukwied; Wolfgang Schleinzer; Michael Ueberall; Christoph Konrad
Journal:  Anesthesiol Res Pract       Date:  2009-10-25

Review 4.  Modulation of pain, nociception, and analgesia by the brain reward center.

Authors:  Vasiliki Mitsi; Venetia Zachariou
Journal:  Neuroscience       Date:  2016-05-14       Impact factor: 3.590

Review 5.  Emerging Roles of Long Non-coding RNAs in Chronic Neuropathic Pain.

Authors:  Wei Wu; Xiaojun Ji; Yang Zhao
Journal:  Front Neurosci       Date:  2019-10-18       Impact factor: 4.677

6.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

7.  Mobile Palliative Care Consultation Service (PCCS): Overview of Hospice and Palliative Care Evaluation (HOPE) Data on In-Patients With End-Stage Cancer, Multiple Sclerosis, and Noncancer, Nonneurological Disease From 4 PCCS Centers in Germany in 2013.

Authors:  Birgit Basedow-Rajwich; Thomas Montag; Andreas Duckert; Christian Schulz; Gennadij Rajwich; Ingo Kleiter; Jürgen Koehler; Gabriele Lindena
Journal:  Palliat Care       Date:  2018-07-18

Review 8.  Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain.

Authors:  Sherelle L Casey; Christopher W Vaughan
Journal:  Medicines (Basel)       Date:  2018-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.